← Abivax S.A. (ABVX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Abivax S.A. (ABVX)
Pharmaceutical Preparations · market cap $7.5B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Abivax S.A. (ABVX) is a Paris-based clinical-stage biotech with 67 employees focused on immune modulation in chronic inflammatory diseases. Its lead asset, ABX464, is in Phase 3 for Ulcerative Colitis, with additional Phase 2 programs in Crohn's Disease (obefazimod), Rheumatoid Arthritis, and HIV, plus a Phase 3 hepatitis B vaccine candidate. The company trades at a ~$7.8B market cap with a consensus strong-buy rating from 11 analysts and a mean price target of ~$160.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Obefazimodimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ABX464 | Phase 3 | Ulcerative Colitis |
| ABX196 | Phase 2 | Carcinoma, Hepatocellular |
| Obefazimod | Phase 2 | Moderately to Severely Active Crohn Disease |
| ABX464 50mg | Phase 2 | Rheumatoid Arthritis |
| ABX464 100 mg | Phase 2 | Ulcerative Colitis |
| ABX464 150mg | Phase 2 | HIV Infections |
| ABX203 therapeutic Hepatitis B vaccine treatment arm | Phase 3 | Chronic Hepatitis B |
Price & technical context
3-month
-34.4%
6-month
-20.3%
12-month
+14.6%
52-wk range
$72.50–$145.31
vs 50-day MA
-17.4%
vs 200-day MA
-19.9%
Realized vol
90.5%
Max drawdown
-58.1%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABVX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.